Distinct lipid/lipoprotein profiles and hormonal responsiveness in nine ethnic groups of postmenopausal Asian women: The Pan-Asia Menopause (PAM) study

References

• Grundy S M, Cleeman J I, Merz C NB, et al. For the Coordinating Committee of the National Cholesterol Education Program. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004; 110: 227–239
   PubMed Web of Science ®Google Scholar
• Sharrett A R, Ballantyne C M, Coady S A, et al. Coronary heart disease prediction from lipoprotein cholesterol levels, triglycerides, lipoprotein(a), apolipoproteins A-I and B, and HDL density subfractions: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 2001; 104: 1108–1113
   PubMed Web of Science ®Google Scholar
• Verschuren W MM, Jacobs D R, Bloemberg B PM, et al. Serum total cholesterol and long-term coronary heart disease mortality in different cultures. Twenty-five year follow-up of the Seven Countries Study. JAMA 1995; 274: 131–136
   PubMed Web of Science ®Google Scholar
• Manson J E, Tosteson H, Ridker P M, et al. The primary prevention of myocardial infarction. N Engl J Med 1992; 326: 1406–1416
   PubMed Web of Science ®Google Scholar
• Wilson P WF, Abbott R D, Castelli W P. High density lipoprotein cholesterol and mortality: The Framingham Heart Study. Atherosclerosis 1988; 8: 737–741
   Google Scholar
• Assmann G, Schulte H, von Eckardstein A, Huang Y. High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport. Atherosclerosis 1996; 124: S11–S20
   PubMed Web of Science ®Google Scholar
• Nicholls S J, Nissen S E. Strategies to promote HDL-C: an emerging therapeutic agent. Eur Heart J 2005; 26: 853–855
   PubMed Web of Science ®Google Scholar
• Stampfer M J, Krauss R M, Ma J, et al. A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 1996; 276: 882–888
   PubMed Web of Science ®Google Scholar
• He Y, Lam T H, Li L S, Li L S, He S F, Liang B Q. Triglyceride and coronary heart disease mortality in a 24-year follow-up study in Xi'an, China. Ann Epidemiol 2004; 14: 1–7
   PubMed Web of Science ®Google Scholar
• Futterman L G, Lemberg L. Lp(a) lipoprotein – an independent risk factor for coronary heart disease after menopause. Am J Crit Care 2001; 10: 63–67
   PubMedGoogle Scholar
• Berglund L, Ramakrishnan R. Lipoprotein(a) an elusive cardiovascular risk factor. Arterioscler Thromb Vasc Biol 2004; 24: 2219–2226
   PubMed Web of Science ®Google Scholar
• Tatsanavivat P, Klungboonkrong V, Chirawatkul A, et al. Prevalence of coronary heart disease and major cardiovascular risk factors in Thailand. Int J Epidemiol 1998; 27: 405–409
   PubMed Web of Science ®Google Scholar
• The InterASIA Collaborative Group. Cardiovascular risk factor levels in urban and rural Thailand – The International Collaborative Study on Cardiovascular Disease in Asia (InterASIA). Eur J Cardiovasc Prev Rehabil 2003; 10: 249–275
   PubMed Web of Science ®Google Scholar
• Nitiyanant W, Ploybutr S, Harntong S, Wasuwat S. Tandhanand S. Lipid and lipoprotein contents in normal Thai subjects. J Med Assoc Thai 1987; 70: 20–23
   PubMedGoogle Scholar
• Yamwong P, Assantachai P, Amornrat A. Prevalence of dyslipidemia in the elderly in rural areas of Thailand. SE Asian J Trop Med Publ Health 2000; 31: 158–162
   PubMedGoogle Scholar
• Chen Z, Peto R, Collins R, MacMahon S, Lu J, Li W. Serum cholesterol concentration and coronary heart disease in a population with low cholesterol concentrations. Br Med J 1991; 303: 276–282
   PubMed Web of Science ®Google Scholar
• Wu Z, Yao C, Zhao D, et al. Cardiovascular disease risk factor levels and their relations to CVD rates in China – results of Sino-MONICA project. Eur J Cardiovasc Prev Rehabil 2004; 11: 275–283
   PubMed Web of Science ®Google Scholar
• Tao S, Li Y, Xiao Z, et al. Serum lipids and their correlates in Chinese urban and rural populations of Beijing and Guangzhou. Int J Epidemiol 1992; 21: 893–903
   PubMed Web of Science ®Google Scholar
• Janus E D, Postiglione A, Singh R B, Lewis B. The modernization of Asia. Implications for coronary heart disease. Circulation 1996; 94: 2671–2673
   PubMed Web of Science ®Google Scholar
• Stefanick M L. Risk-benefit profiles of raloxifene for women. N Engl J Med 2006; 355: 190–192
   PubMed Web of Science ®Google Scholar
• Rosengren A, Hawken S, Ôunpuu S, et al. For the INTERHEART investigators. Association of psychosocial risk factors with risk of acute myocardial infarction in 11 119 cases and 13 648 controls from 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 953–962
   PubMed Web of Science ®Google Scholar
• Yusuf S, Hawken S, Ôunpuu S, et al. For the INTERHEART Study investigators. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364: 937–952
   PubMed Web of Science ®Google Scholar
• Tan D, Haines C J, Limpaphayom K K, Holinka C F, Ausmanas M K. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia Menopause (PAM) study. Maturitas 2005; 52: 35–51
   PubMed Web of Science ®Google Scholar
• Haines C J, Xing S -M, Park K -H, Holinka C F, Ausmanas M K. Prevalence of menopausal symptoms in different groups of Asian women and responsiveness to therapy with three doses of conjugated estrogens/medroxyprogesterone acetate: The Pan-Asia Menopause (PAM) study. Maturitas 2005; 52: 264–276
   PubMed Web of Science ®Google Scholar
• Limpahayom K K, Darmasetiawan M S, Hussain R I, Burriss S W, Holinka C F, Ausmanas M K. Differential prevalence of quality-of-life categories in Asian women and changes after therapy with three doses of conjugated estrogens/medroxyprogestorone acetate: the Pan-Asia Menopause (PAM) study. Climacteric 2006; 9: 1–11
   Google Scholar
• Haines C, Chung T, Chang A, Masarei J, Tomlinson B, Wong E. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. Arch Intern Med 1996; 156: 866–872
   PubMed Web of Science ®Google Scholar
• Ridker P M, Rifai N, Cook N R, Bradwin G, Buring J E. Non-HDL cholesterol, apolipoproteins A-1 and B100, standard lipid measures, lipid ratios, and CRP as risk factors for cardiovascular disease in women. JAMA 2005; 294: 326–333
   PubMed Web of Science ®Google Scholar
• Walldius G, Jungner I, Holme I, Aastveit A H, Kolar W, Steiner E. High apolipoprotein B, low apolipoprotein A-1, and improvement in the prediction of fatal myocardial infarction (AMORIS study): a prospective study. Lancet 2001; 358: 2026–2033
   PubMed Web of Science ®Google Scholar
• Jungner I, Sniderman A D, Furberg C, Aastveit A H, Holme I, Walldius G. Does low-density lipoprotein size add to atherogenic particle number in predicting the risk of fatal myocardial infarction?. Am J Cardiol 2006; 97: 943–946
   PubMed Web of Science ®Google Scholar
• Sniderman A D, Junger I, Holme I, Aastveit A, Walldius G. Errors that result from using the TC/HDL C ratio rather than the apoB/apoA-1 ratio to identify the lipoprotein-related risk of vascular disease. J Intern Med 2006; 259: 455–461
   PubMed Web of Science ®Google Scholar
• Chew W LS, Mah P K, Tan Y T, Cheong C K. A comparison of the levels of total serum cholesterol (1974–1984) and its relations to ischaemic heart disease in Singapore and the United States of America. Sing Med J 1988; 29: 6–10
   PubMedGoogle Scholar
• Dwyer T, Emmanuel S C, Janus E D, Wu Z, Hynes K L, Zhang C. The emergence of coronary heart disease in populations of Chinese descent. Atherosclerosis 2003; 67: 303–310
   Google Scholar
• Woo K S, Chook P, Young R P, Sanderson J E. New risk factors for coronary heart disease in Asia. Int J Cardiol 1997; 62(Suppl 1)S39–S42
   PubMedGoogle Scholar
• Khor G L. Cardiovascular epidemiology in the Asia-Pacific region. Asia Pac J Clin Nutr 2001; 10: 76–80
   PubMed Web of Science ®Google Scholar
• Zhou B F, Stamler J, Dennis B, et al. Nutrient intakes of middle-aged men and women in China, Japan, United Kingdom, and United States in the late 1990s: The INTERMAP Study. J Hum Hypertens 2003; 17: 623–630
   PubMed Web of Science ®Google Scholar
• Pan W -H, Chiang B N. Plasma lipid profiles and epidemiology of atherosclerotic diseases in Taiwan – a unique experience. Atherosclerosis 1995; 118: 285–295
   PubMed Web of Science ®Google Scholar
• Williams B. Westernised Asians and cardiovascular disease: nature or nurture. Lancet 1995; 345: 401–402
   PubMed Web of Science ®Google Scholar
• Khoo K L, Tan H, Liew Y M, Deslypere J P, Janus E. Lipids and coronary heart disease in Asia. Atherosclerosis 2003; 169: 1–10
   PubMed Web of Science ®Google Scholar
• Reddy K S, Yusuf S. Emerging epidemic of cardiovascular disease in developing countries. Circulation 1998; 97: 596–601
   PubMed Web of Science ®Google Scholar
• Bhatnagar D, Anand I S, Durrington P N, et al. Coronary risk factors in people from the Indian subcontinent living in West London and their siblings in India. Lancet 1995; 345: 405–409
   PubMed Web of Science ®Google Scholar
• Hughes K, Lun K C, Yeo P PB. Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. I. Differences in mortality. J Epidemiol Commun Health 1990; 44: 24–28
   PubMed Web of Science ®Google Scholar
• Hughes K, Yeo P PB, Lun K C, et al. Cardiovascular diseases in Chinese, Malays, and Indians in Singapore. II. Differences in risk factor levels. J Epidemiol Commun Health 1990; 44: 29–35
   PubMed Web of Science ®Google Scholar
• Wild S H, Laws A, Fortmann S P, Varady A N, Byrne C D. Mortality from coronary heart disease and stroke for six ethnic groups in California, 1985 to 1990. Ann Epidemiol 1995; 5: 432–439
   PubMedGoogle Scholar
• Balarajan R. Ethnicity and variations in mortality from coronary heart disease. Health Trends 1996; 28: 45–51
   Google Scholar
• Sheth T, Nair C, Nargundkar M, Anand S, Yusuf S. Cardiovascular and cancer mortality among Canadians of European, south Asian and Chinese origin from 1979 to 1993: an analysis of 1.2 million deaths. Can Med Assoc J 1999; 161: 132–138
   PubMed Web of Science ®Google Scholar
• Anand S S, Yusuf S, Vuksan V, et al. Differences in risk factors, atherosclerosis, and cardiovascular disease between ethnic groups in Canada: the Study of Health Assessment and Risk in Ethnic groups (SHARE). Lancet 2000; 356: 279–284
   PubMed Web of Science ®Google Scholar
• Lobo R A, Bush T, Carr B R, Pickar J H. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. Fertil Steril 2001; 76: 13–24
   PubMed Web of Science ®Google Scholar
• Chang T -C, Lien Y -R, Chen M, Cheng S -P, Chen R -J, Chow S -N. Effect of conjugated equine estrogen in combination with two different progestogens on the risk factors of coronary heart disease in postmenopausal Chinese women in Taiwan: a randomized one-year study. Acta Obstet Gynecol Scand 2004; 83: 661–666
   PubMed Web of Science ®Google Scholar
• Haines C J, Chung T KH, Masarei J RL, Tomlinson B, Lau J TF. An examination of the effect of combined cyclical hormone replacement therapy on lipoprotein(a) and other lipoproteins. Atherosclerosis 1996; 119: 215–222
   PubMed Web of Science ®Google Scholar
• Barrett-Connor E. Hormone replacement therapy, heart disease, and other considerations. Ann Rev Publ Health 1998; 19: 55–72
   PubMed Web of Science ®Google Scholar
• Rossouw J E, Anderson G L, Prentice R L, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. JAMA 2002; 288: 321–333
   PubMed Web of Science ®Google Scholar
• Herrington D M, Reboussin D M, Brosnihan K B, et al. Effects of estrogen replacement on the progression of coronary-artery atherosclerosis. N Engl J Med 2000; 343: 522–529
   PubMed Web of Science ®Google Scholar
• Grady D, Herrington D, Bittner V, et al. Cardiovascular disease outcomes during 6.8 years of hormone therapy. Heart and Estrogen/progestin Replacement Study Follow-up (HERS II). JAMA 2002; 288: 49–57
   PubMed Web of Science ®Google Scholar
• Hodis H N, Mack W J, Lobo R. What is the cardioprotective role of hormone replacement therapy?. Curr Atheroscler Rep 2003; 5: 56–66
   PubMedGoogle Scholar
• Naftolin F, Taylor H S, Karas R, et al. The Women's Health Initiative could not have detected cardioprotective effects of starting hormone therapy during the menopausal transition. Fertil Steril 2004; 81: 1498–1501
   PubMed Web of Science ®Google Scholar
• Pines A, Sturdee D W, Birkhäuser M. on behalf of the International Menopause Society. More data on hormone therapy and coronary heart disease: Comments on recent publications from the WHI and Nurses' Health Study. Climacteric 2006; 9: 75–76
   PubMed Web of Science ®Google Scholar
• Manson J E, Bassuk S S, Harman S M, et al. Postmenopausal hormone therapy: new questions and the case for new clinical trials. Menopause 2006; 13: 139–147
   PubMed Web of Science ®Google Scholar
• Leowattana W, Bhuripanyo K, Worawattananon P, Mahanonda N, Pokum S. Correlation of serum lipoprotein(a) with the clinical presentation of Thai coronary artery disease patients. J Med Assoc Thai 2000; 83(Suppl 2)S194–S198
   PubMedGoogle Scholar